Veklury (Remdesivir) retained antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…
On Feb. 9, 2022, the Indiana Department of Health confirmed that a case of H5N1 highly pathogenic avian…
On Feb. 8, 2022, Moderna announced a new supply agreement with the government of Colombia for 10.8 million…
On Feb. 8, 2022, Merck and Ridgeback Biotherapeutics announced that a total of 3.1 million courses of molnupiravir,…
On Feb. 8, 2022, a research team led at Boston University School of Public Health reported on links…
On Feb. 8, 2022, researchers at Oxford University announced they had implanted a novel closed-loop research platform for…
On Feb. 7, 2022, researchers at Washington University School of Medicine in St. Louis announced an analysis of…
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
On Feb. 3, 2022, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected Omicron COVID-19 subvariants BA.1, BA.2, and…
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
On Feb. 2, 2022, NIAID scientists announced the new Pandemic Preparedness Plan aimed to support critical basic and…
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
On Jan. 31, 2022, Moderna announced the U.S. Food and Drug Administration (FDA)Â had approved the Biologics License…
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…
On Jan, 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
On Jan. 24, 2022, Pfizer and BioNTech announced the publication of new results from two laboratory studies demonstrating…
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
On Jan. 24, 2022, Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that it had leveraged its novel…
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
On Jan. 14, 2022, the U.S. Department of Agricultureï¾’s National Veterinary Services Laboratories confirmed a highly pathogenic Eurasian…
On Jan. 14, 2022, the U.S. Department of Defense, in coordination with the U.S. Department of Health and…